While the overall treatment strategy and drug options are relatively well-defined for HER2-positive breast cancer, and the dual-targeted therapy with trastuzumab plus pertuzumab is still the standard neoadjuvant regimen, the development of more drugs such as TKIs can enrich clinical treatment options. This evidence concerns the gene ERBB2 and breast carcinoma.